相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Michael Wang et al.
BLOOD (2008)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Clinically relevant end points and new drug approvals for myeloma
K. C. Anderson et al.
LEUKEMIA (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Lenalidomide in the treatment of multiple myeloma
Kamakshi V. Rao
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2007)
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer
Charles L. Bennett et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
BLOOD (2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Current treatment options for myeloma
E Terpos et al.
EXPERT OPINION ON PHARMACOTHERAPY (2005)
Clinical course of patients with relapsed multiple myeloma
SK Kumar et al.
MAYO CLINIC PROCEEDINGS (2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
T Hideshima et al.
NATURE REVIEWS CANCER (2002)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
分享论文
